0,drives
1,haemodynamic
2,ffm
3,post-dash
4,congenital lesions
5,moderate-quality
6,clinical practice guideline
7,flow
8,wave ratio
9,central blood pressure
10,single-cohort
11,conjoint education
12,led
13,bound
14,ctnt
15,rv
16,dynamics
17,branch
18,purpose of review
19,peripheral
20,furosemide
21,heart failure clinic
22,development
23,hemostasis
24,organ
25,endothelial repair
26,collected
27,ischemic
28,dd
29,specialty hospital
30,energy expenditure
31,end-systolic
32,partial attenuation
33,25th-75th
34,at-risk
35,angiotensin-receptor
36,meta-analyzed mortality
37,.97s
38,differences
39,undergoing
40,australian
41,ascertain
42,is
43,centrimag
44,cardioprotective
45,mitogen-activated
46,anthracycline
47,standardized
48,challenging
49,von willebrand factor
50,superfamily
51,knockdown
52,basal
53,time of surgery
54,ms
55,inpatient admissions
56,patterning
57,osprey
58,large-scale
59,observational cohort studies
60,vagal
61,pro-brain-type
62,arg83gly
63,skilled
64,following
65,underlies
66,t2
67,borderline
68,breakdown
69,non-frail
70,morphological
71,myofilament
72,testing
73,exchange
74,post
75,self-management
76,12-lead ecg
77,moderate-severe
78,associated
79,systemic / uv treatment
80,introduced
81,regional
82,percent of hospitals
83,presenting
84,growth factor-β
85,placebo-controlled
86,sparing
87,c=24.3
88,filling
89,implantation
90,quality of life
91,clinics
92,poc
93,toxicity
94,decreases
95,chromatin
96,xo-mediated
97,raloxifene-treated
98,coagulability
99,shotgun
100,biosynthetic
101,food-frequency
102,patient-level regression
103,cognitive
104,in
105,through
106,hazard ratios
107,coated
108,relative
109,methods
110,resting
111,descending
112,first-time
113,non-urbanized
114,hemocompatibility
115,currents
116,qrs
117,axis
118,channel
119,approach
120,pulse-wave velocity
121,splice
122,spectral
123,converts
124,heart failure mortality
125,abrogated
126,curve
127,hyperlipidaemia
128,subunit
129,identification
130,work rate
131,second-generation
132,left ventricle end-diastolic pressure
133,post-acute care transfer
134,nanomolar
135,us
136,prodrug
137,gg
138,outperformed
139,acute right heart failure
140,independently
141,chf-inv
142,wide
143,processes of care delivery
144,network
145,aldosterone
146,interquartile range
147,amelioration
148,quality-adjusted survival
149,raloxifene
150,randomised-controlled
151,hydrolytic
152,regulatory
153,quarterly inpatient admissions
154,gdmt
155,subscales
156,length-force
157,inoperable
158,pre-pd
159,extubated
160,non-lbbb
161,limits of agreement
162,progression
163,load-corrected
164,actin cytoskeleton
165,left ventricular filling
166,criteria
167,relationship
168,recent
169,units
170,deposition
171,consumption rate
172,clinical diastolic
173,structured
174,antirheumatic
175,inotropic
176,bundle
177,idiopathic
178,retrospective
179,office-based
180,guide
181,sustainability
182,study design
183,left
184,norepinephrine-induced
185,levitated
186,aging
187,defibrillator
188,formalism
189,eseptal
190,crt-d
191,ste
192,ref
193,parasympathetic
194,developed
195,short-term
196,proportional hazards
197,severity of heart failure
198,noncardiovascular
199,developmental impairment
200,exercise per week
201,inotropes
202,setting
203,myocardial perfusion
204,b-treated
205,sts
206,hepatic
207,dxa
208,stimulation
209,low-frequency
210,uncertain
211,data extraction
212,case-fatality
213,methodology
214,lean body mass
215,develop
216,assays
217,right-sided
218,black race
219,haemodynamic stress
220,young adults
221,suppression
222,responsive
223,dl
224,study-drug
225,study
226,improved
227,phosphorylation
228,cyclic
229,recreational
230,mitral regurgitation
231,up-regulated
232,differential response
233,all-cause hospitalizations
234,characterize
235,cardiac hypertrophy
236,breathing control
237,secondary end points
238,transoesophageal echocardiographic
239,magnetic resonance
240,brain
241,divided
242,murmurs
243,post-translational state
244,modeling
245,distressing
246,wilcoxon
247,nondiabetic
248,murmur
249,breath-holding
250,biomedical
251,heart failure hospitalization
252,composite endpoint
253,passive
254,cornerstone
255,v.6.2
256,cost-minimization
257,replacement
258,β-ar
259,acetyltransferases
260,phase of the disease
261,timing
262,dynamic
263,iron
264,denotes
265,magnetic resonance imaging
266,nuts
267,erythropoiesis-stimulating agent
268,second
269,race
270,primary
271,myocardial t1
272,briefing
273,ankle-brachial
274,inroads
275,and
276,under 35
277,athletes
278,intima-media
279,community
280,savings
281,postmenopausal
282,blood transfusions
283,emergency room
284,frame
285,slows
286,caring
287,amyloidosis
288,hfpef
289,dogs
290,burden of heart failure hospitalizations
291,nonsurvivors
292,orientation
293,natural
294,unchanged
295,beginning
296,myocardial changes
297,feeding
298,aortic constriction
299,confidence level
300,ven
301,renin-angiotensin-aldosteron
302,biomarker
303,overexpression
304,uptitrations
305,progenitor
306,show
307,frequency of administration
308,reporting
309,toronto
310,btes
311,time of discharge
312,sudden death
313,central venous pressure
314,early-onset
315,shorter
316,differential impact
317,frailty
318,anthracycline-treated
319,levitated rotor
320,systems level
321,going
322,theory
323,activators
324,indeterminable
325,electron microscopy
326,downward regression line
327,mir-25
328,α-subunit
329,embedded
330,ras
331,latin america
332,kaplan-meier
333,congenital heart lesions
334,titin
335,follow
336,sample
337,instability
338,computed
339,exhaustion
340,cytotoxic
341,molecular level
342,protection
343,rs
344,community-based
345,international
346,myocardial ischaemia
347,c-kit
348,stroke
349,ventricular
350,sodium-restricted
351,scarce
352,conscious
353,growth
354,induction
355,single-institution
356,retrieved
357,antitumor
358,urban
359,cardiomyocytes
360,all-cause hospitalization
361,natriuretic peptide
362,extended
363,cohort
364,turbulence
365,12-week
366,anastomosis
367,absorption
368,kidney
369,first-in-class
370,lvet
371,k=252
372,add-on
373,nontrastuzumab
374,bisoprolol
375,progress
376,camp
377,midwestern state
378,postoperative survival
379,clinical response
380,wk
381,adenosine
382,hall
383,action potential
384,left ventricular longitudinal systolic strain
385,subgroups
386,walk
387,nps
388,fewer st-segment-elevation
389,receptor
390,leaflet
391,electrolytes
392,actin
393,aric
394,overexpressing
395,pathology
396,clinical change
397,transcription factor
398,precapillary
399,hospitalisation
400,sternal
401,adenoviral vector encoding
402,pathological heart
403,clear
404,heart failure-related
405,progenitor cells
406,catheter
407,left ventricle
408,egfr
409,substitution
410,small-molecule
411,cardioverter
412,preventing
413,high-volume
414,underlying
415,uninephrectomy
416,controlled
417,brachial systolic pressure
418,strengths
419,research design
420,regulator
421,controlling
422,unilateral
423,relies
424,myofibrillar
425,decades
426,pump
427,6-wk
428,partial pressure
429,pneumonia
430,preoperative serum
431,counteracted
432,periprocedural
433,mapping
434,myocarditis
435,beta-blocker
436,aortic pressure curve
437,10-cell
438,technique
439,toward
440,genetic
441,sport
442,logistic
443,randomly
444,evidence-based
445,congestive heart failure
446,single-payer
447,cpet
448,infarcted
449,signalling
450,side effects
451,high-density
452,samples
453,sympathetic nervous systems
454,embolism
455,blockers
456,atrial explant-derived
457,throughout
458,nuclear factor
459,arm cuff
460,peripheral edema
461,4-year survival
462,de novo
463,allogeneic
464,heavy chain
465,'d
466,unsuitable
467,icu
468,va-rt cohorts
469,undergo
470,first-ever
471,crt
472,lower peak vo2
473,spironolactone
474,responsiveness
475,extracted
476,jehovah
477,sequential phosphorylation
478,histologic
479,evolution
480,perioperative
481,left anterior
482,r=0.67
483,looping
484,anemia
485,antagonism
486,calreticulin
487,reviewers
488,effect
489,prediction
490,postnatal
491,decile
492,transfusions
493,slope
494,acid
495,vo2max
496,secretion
497,exacerbates
498,separately
499,covariate
500,sst2
501,critical
502,september
503,hospitalized
504,adenine
505,off-pump
506,antiplatelet
507,tolerated
508,subclass
509,nuclear factor-κb
510,serum potassium
511,diuretic refractory
512,myocardial oxygen
513,be
514,altering
515,if-channel
516,ejection fraction
517,stenosis
518,emean
519,action potentials
520,baseline electrocardiogram
521,czech republic
522,opposing
523,series
524,organic
525,extreme
526,acute care
527,pf
528,co-activating
529,anthracycline-containing
530,hypotension
531,increase in parasympathetic tone
532,etiology
533,intubation
534,covariates
535,systole
536,al. show
537,substudy
538,screening
539,shunt
540,guideline-directed medical therapy
541,hh
542,peripheral muscles
543,center
544,namely
545,after
546,myofibre
547,st2
548,anthracycline-related
549,receptors
550,undergone
551,randomization
552,principal
553,cardioverter-defibrillators
554,exerted
555,common underlying
556,with.estimates
557,classified
558,prone
559,eplerenone
560,weak
561,her
562,elicited
563,extrapolating
564,conditioning
565,tricuspid
566,eo-cfus
567,slowness
568,eccentric
569,n=100
570,elastic
571,was
572,20-week
573,clinic
574,renin-angiotensin
575,propensity-score
576,morphology
577,reduction in risk
578,extracorporeal
579,myxoma
580,p38alpha
581,operationalized hospital
582,long
583,unloads
584,incentives
585,affects
586,co-morbidity
587,hemodynamically
588,ranging
589,3-vessel
590,extensive
591,bradycardic
592,madit-crt
593,partly
594,blood loss
595,neonatal
596,general linear
597,overlapping
598,recurrent
599,dithiothreitol
600,defibrillator-only
601,tac
602,icds
603,s'septal
604,importance
605,in-trial
606,proportional hazard
607,adenylyl cyclase
608,cross-linking
609,vena cava
610,carvedilol
611,tta
612,enos-thr
613,age-dependent
614,i.p.
615,red blood cell transfusion
616,coronary artery
617,cardiology
618,patients
619,suboptimal
620,caloric restriction
621,pre-hct
622,velocities
623,childhood
624,pacing-induced
625,american college of physicians
626,northwest united states
627,overload
628,anthracycline-induced
629,ka
630,myosin
631,kaplan-meier curves
632,step
633,cox
634,methylatropine
635,well-treated
636,practice settings
637,aortic
638,halts
639,human-to-machine
640,sci
641,depressed
642,interpretation
643,to
644,testosterone
645,measures of functional capacity
646,pairwise
647,flow velocities
648,mice
649,time of inclusion
650,unintentional
651,university hospital
652,converting
653,reductions
654,left ventricular hypertrophy
655,patient-years
656,pharmaceutically
657,nonterminal epitopes
658,medicare inpatient
659,xo
660,isolated
661,differentiation
662,quality-of-life
663,originating
664,venous thromboembolic
665,avp
666,tapse
667,define
668,transduction pathways
669,multivariate-adjusted
670,deciles
671,plasty
672,first-in-man
673,warranted
674,non-dilated
675,myocytes
676,efficacy
677,lusitropic
678,diet scores
679,bridging
680,closure
681,stable
682,antagonist
683,inhibitor
684,sd
685,pathophysiology
686,protective peptides
687,pathobiology
688,sensitivity
689,propensity score-matched
690,flow-mediated dilatation diameter
691,vo2
692,heartmate
693,arrhythmias
694,endothelial-protective
695,hemodynamics
696,upstream
697,non-dnx
698,x12
699,macrophages
700,western society
701,supporting
702,home
703,antihyperglycemic
704,long-term survival
705,tests
706,inability
707,non-aas
708,treatments
709,outpatient settings
710,genomic scale
711,lacking
712,witness
713,beneficial
714,feet
715,systolic elastance
716,aforementioned
717,combination
718,therapeutic
719,vasopressin
720,relieve
721,cohorts
722,decision-support
723,delayed
724,aged
725,stabilize
726,vad
727,aldosterone receptor
728,non-randomized
729,free-breathing
730,circulating
731,cardiomyopathic
732,deals
733,real-world
734,right ventricular-pulmonary
735,instituting
736,university health network
737,fibrillation
738,writer
739,affecting
740,abrogate
741,dialysis
742,lvas
743,in-hospital
744,comanagement
745,cochrane
746,tug
747,primary endpoint
748,predicting
749,voltage-gated ca
750,cellular plasticity
751,e'septal
752,atrium
753,commoner
754,exercise-induced
755,limitation
756,myocardium
757,penalties
758,expenditure
759,paralleled
760,inflammation
761,inpatient
762,ea
763,internal
764,hart
765,ie
766,drive
767,cronbach
768,x-ray absorptiometry
769,isoenzymes
770,cell yield
771,camp-dependent
772,transplant
773,infancy
774,interatrial shunt
775,aiming
776,cardiologist
777,12-s
778,gene
779,peripheral muscle pump
780,decongestion
781,splicing
782,factorial
783,pre-post comparisons
784,interatrial
785,sympathetic tone
786,hemoglobin
787,eligibility
788,carbohydrates
789,sternotomy
790,non-biological
791,thigh
792,age of 62
793,randomized controlled trial
794,outweigh
795,atrial fibrillation
796,statistics
797,nonadherence
798,basal rotations
799,qt
800,aortic valve
801,ventricular fibrillation
802,alternatives
803,point of care
804,β1ar
805,p=0.036
806,inverse
807,overview
808,computational
809,cause of death
810,measuring
811,stem cell-derived
812,telephone
813,obesity
814,washout
815,reference
816,kappa coefficients
817,management
818,calf
819,p38
820,forward
821,glomerular
822,behavioural-change
823,collinearity
824,scaffolds
825,body mass index
826,function
827,angiotensin
828,five
829,mitral stenosis
830,review
831,education
832,encoding
833,differential g-protein
834,etiologies
835,whites
836,sympathovagal
837,examination
838,median
839,population-specific
840,saf
841,vitro
842,stage
843,interest
844,integral
845,dilatation
846,t1-mapping
847,full potential
848,cytochrome
849,systematically
850,readmissions
851,anaesthesia
852,compensated
853,elevations
854,paradigm-hf
855,complexities
856,kg
857,et
858,multihospital
859,guideline-recommended
860,modulates
861,routinely
862,peripheral vascular
863,follow-up
864,fatigue
865,leading
866,tonometric
867,clinical trial
868,pilot
869,gas
870,coding
871,ventricles
872,randomised
873,post-hct
874,mirnas
875,index
876,resistant
877,third
878,bcl2
879,decreased
880,changing
881,explant-derived
882,permeability
883,health system
884,cardiomyocyte bioenergetics
885,middle-aged
886,article
887,unclear
888,event-free
889,new onset
890,high-fat
891,ip
892,6-month
893,followed-up
894,explant
895,hyperkalemia
896,fluid
897,angiotensin-aldosterone
898,study cohort
899,density
900,well
901,metoprolol
902,performed
903,period of low bp
904,differential effect
905,thrombotic
906,adherence
907,left ventricular biopsies
908,malfunctioning
909,exercise
910,acetyl-lysine
911,segment
912,treadmill
913,ventricular mass
914,family
915,2-fold
916,elucidate
917,bromodomain-containing
918,cm2
919,cpg
920,regulated
921,tolvaptan
922,ai
923,nonselective
924,nondiabetes
925,cycle
926,inhibitors
927,intricately
928,trial
929,impact
930,myocardial angiogenesis
931,reverse
932,myocardial tissues
933,catheter system
934,blocker
935,surrogate
936,exacerbation
937,multisystem
938,along
939,transition
940,activating
941,connected
942,on the same day
943,re-express
944,reduction
945,european
946,excised
947,channelopathies
948,tertiary
949,hospital
950,i-iii
951,medium
952,noncoding
953,free mass
954,analyses
955,unfit
956,per os
957,hm
958,two-vessel
959,body mass
960,compensatory
961,blockade
962,from
963,2008-june
964,swine
965,trichrome
966,solid
967,outflow
968,left ventricular ejection
969,reversed
970,atheromatous
971,resulting
972,chelation
973,metabolism
974,overwhelming
975,quality of life score
976,transthoracic echocardiography
977,protein
978,lc-ms
979,alternative
980,throughput
981,bnp
982,deficits
983,self-rated
984,technology
985,sodium
986,acr
987,non-sudden
988,indicative
989,refractory
990,myocyte-specific
991,net-reclassification-improvement
992,muscles
993,health insurance board
994,refractory cardiogenic shock
995,imbalance
996,reclassification
997,mechanical circulatory
998,processing
999,adjunctive
1000,system
1001,mistargeting
1002,signal transduction
1003,3-min
1004,unaltered
1005,interaction
1006,insulin
1007,real world
1008,ahf
1009,renal dnx
1010,life expectancy
1011,influx
1012,signalling pathway
1013,health care providers
1014,clinical studies
1015,type
1016,investigating
1017,isoprenaline infusion
1018,exacerbated
1019,electromechanical delay
1020,matched
1021,clinically
1022,systemic hypertension
1023,myocardial ischemia
1024,malfunctions
1025,switched
1026,signaling pathways
1027,re-activating
1028,storm
1029,revascularization
1030,rounds
1031,cardiac angiogenesis
1032,low-risk
1033,thrombosis
1034,muscular
1035,shortening
1036,measurement
1037,aerobic
1038,angiotensin-converting
1039,fatty acids
1040,hospital-to-home
1041,baseline
1042,hf
1043,vs
1044,post-lvad
1045,risk of death
1046,lifesaving
1047,speckle
1048,flow velocity
1049,downregulation
1050,mitochondrial respiration
1051,north america
1052,multivariable
1053,modern
1054,lean mass
1055,downstream
1056,admission
1057,cis
1058,hct
1059,steady
1060,california
1061,emergency department
1062,tunel
1063,randomized
1064,cross-sectional
1065,cardiopulmonary
1066,regional circumferential strain
1067,tachyarrhythmias
1068,risk factors
1069,transverse
1070,above
1071,activate
1072,new-onset
1073,radioenzymatic
1074,underperfusion
1075,plasticity
1076,iron homeostasis
1077,lower
1078,predictor
1079,early-activated
1080,long-term
1081,hf-related
1082,cost-effective
1083,rnas
1084,findings
1085,pharmacologic
1086,transferred
1087,contact
1088,pg
1089,advances in treatment
1090,doctors
1091,partial
1092,end
1093,anesthetized
1094,younger
1095,isoforms
1096,ros
1097,anaerobic
1098,proof-of-principle
1099,harms
1100,interconnected
1101,normalization
1102,regression line
1103,induce
1104,rrna
1105,commissioning
1106,ami
1107,conventional
1108,reduce
1109,intubations
1110,n=71
1111,right
1112,single-centre
1113,matched-pairs
1114,muscle-wasting
1115,acute
1116,peritoneal dialysis
1117,institutions
1118,hf-action
1119,improves
1120,hand-searching
1121,acetylcholinesterase
1122,genotyped
1123,variables
1124,proangiogenic
1125,myocardial phosphodiesterase-2
1126,accounted
1127,left ventricular ejection fraction
1128,transduction
1129,production
1130,primary end point
1131,activated
1132,post-myocardial infarction
1133,therapeutics
1134,atrial pacing
1135,diet
1136,database
1137,pathway
1138,channels
1139,confer
1140,bet
1141,anthracyclines
1142,serious
1143,incubated
1144,coefficient
1145,three
1146,fundamental
1147,differentially
1148,fall into stage
1149,foundation
1150,analyze
1151,outpatients
1152,fes
1153,collect
1154,flow reserve
1155,post-tac
1156,6-mwt
1157,diuretics
1158,echocardiography
1159,embryonic kidney
1160,methotrexate
1161,ivabradine
1162,autonomic
1163,competitive collateral
1164,perturbed
1165,pulseless
1166,renal
1167,nurse
1168,all-cause
1169,distinguish
1170,lower cd34+vegfr2
1171,walking
1172,risk-adjusted mortality
1173,joint associations
1174,beta-blockers
1175,percutaneous coronary revascularization
1176,contextual factors
1177,japanese
1178,statistically
1179,offset
1180,principle
1181,physicians
1182,elateral
1183,brd4
1184,tactics
1185,four-week
1186,doxorubicin-induced
1187,schfi
1188,cooperate
1189,adjuvant setting
1190,kappa coefficient
1191,decoy
1192,myocardial infarction
1193,derivation cohort
1194,clinical data
1195,postoperative echocardiography
1196,inappropriate therapy
1197,cogeneration
1198,beat
1199,translational repression
1200,carries
1201,'s
1202,per cent
1203,index admission
1204,myocardial extracellular matrix
1205,peak
1206,linear
1207,peak oxygen
1208,interplay
1209,phenylephrine-induced
1210,external
1211,e'lateral
1212,ras-blocker
1213,coupling
1214,stimuli
1215,breast
1216,study-related
1217,spectrometry
1218,sickle cell
1219,canine electromechanics
1220,strategy
1221,poorly
1222,cutoff
1223,bridged
1224,left ventricular systolic
1225,date of death
1226,70y
1227,postoperative
1228,gender-matched
1229,percutaneous revascularization
1230,subspecialty
1231,nodularity
1232,old
1233,pressures
1234,trend
1235,cost per patient
1236,pressure-overload-induced hypertrophy
1237,are
1238,cross talk
1239,alive
1240,10-eo-cfu
1241,pre-crt
1242,electronic
1243,primary care clinicians
1244,enhanced
1245,ratio
1246,protective
1247,confidence interval
1248,continuous-flow
1249,advocate
1250,defibrillator-crt
1251,diastolic
1252,lad
1253,qol
1254,attenuation
1255,open-label
1256,decongestion end point
1257,hdl-mediated
1258,noncardiac
1259,myocardial ischemic
1260,long-term mortality
1261,cardiovascular
1262,mixed linear
1263,new-user cohort study
1264,changes
1265,measured
1266,body mass ratio
1267,clinical care delivery
1268,pressure-volume
1269,β-blocker
1270,traditional
1271,lbbb
1272,stems
1273,training-induced
1274,signaling
1275,effector
1276,haematopoietic
1277,control
1278,shifted
1279,hand
1280,referral centre
1281,pathogenesis
1282,approaches
1283,new zealand
1284,viscoelastic
1285,iron deficiency
1286,ranked
1287,long-acting
1288,risk factor
1289,increase
1290,tobacco
1291,strengthen
1292,lateral wall
1293,young athletes
1294,radiological
1295,striking
1296,procedures
1297,readmission
1298,cinahl
1299,albumin
1300,translating
1301,regression
1302,transient
1303,4-fold
1304,8-fluo-camp
1305,prostate
1306,responses
1307,aggravate
1308,general
1309,canine
1310,externally
1311,decreased in the chf-inv
1312,mri
1313,obese zsf1
1314,range
1315,time-varying
1316,end-diastolic
1317,trans
1318,fractional area
1319,operating
1320,mr-proadm
1321,heart rate
1322,two-center
1323,inactive
1324,correlated
1325,ees
1326,medicare
1327,right ventricular
1328,downregulated
1329,angiography
1330,link
1331,peak o2 per kilogram
1332,muscle
1333,pathways
1334,rehospitalization
1335,paediatric heart failure
1336,net
1337,binomial regression models
1338,faster turnaround
1339,right atrium mass
1340,cardiography
1341,pathophysiological
1342,transitions
1343,sepsis
1344,nontreatment
1345,generator
1346,tested
1347,tnf
1348,chromatin-associated
1349,angiotensin receptor
1350,alendronate-
1351,research
1352,late-onset
1353,hemolysis
1354,chf-nyha-iiib
1355,between
1356,cognitive impairment
1357,erk1
1358,fixed ring
1359,adaptive
1360,investigate
1361,rehabilitation
1362,movement
1363,clinical comparisons
1364,bypass
1365,bisphosphonates
1366,integrates
1367,driven
1368,ecct
1369,surrogates
1370,depresses
1371,with
1372,aac
1373,eh
1374,nonfatal
1375,nt-probnp
1376,alendronate
1377,practices
1378,25mg
1379,ameliorated
1380,change in distribution
1381,adamantly
1382,coexist
1383,lf
1384,centers
1385,relative reduction
1386,impaired
1387,interact
1388,congestion-like
1389,canadian cardiovascular society
1390,clinical prediction
1391,max
1392,collagen
1393,protocol
1394,hearts
1395,band
1396,exertion
1397,positive
1398,placebo
1399,systemic vascular resistance
1400,edge-to-edge
1401,acute ischemic right heart failure
1402,duration
1403,validate
1404,heart function clinic
1405,resistance
1406,encouraging
1407,quasi-experiment
1408,within
1409,zsf1
1410,hf-induced
1411,mva
1412,relaxation
1413,right ventricular contractile reserve
1414,rhythm
1415,threshold
1416,postcontrast
1417,time-domain
1418,support
1419,risk-standardized
1420,measure
1421,trials
1422,non-hf
1423,peripheral abnormalities
1424,drug administration
1425,change
1426,doxorubicin
1427,leg
1428,combinations
1429,measures
1430,high-strength
1431,lv
1432,pka
1433,health service
1434,candesartan
1435,human
1436,contracting
1437,arthritis
1438,referrals
1439,inotrope-dependent
1440,preoperative
1441,it
1442,particles
1443,multiple-procedure
1444,magnetic resonance spectroscopy
1445,thickness
1446,incorporated
1447,404.x1
1448,pro-brain
1449,sitagliptin
1450,30-day
1451,involved
1452,life-threatening
1453,abolished
1454,mrnas
1455,man
1456,clinical excellence
1457,western australia
1458,workload
1459,multiorgan
1460,progressive
1461,progressed
1462,discrepancy
1463,body
1464,involving
1465,erasers
1466,white
1467,hallmark
1468,young
1469,hdl
1470,high-dose
1471,pb
1472,continuity equation
1473,shortens
1474,systolic
1475,block
1476,tachy
1477,balance
1478,underwent
1479,quick
1480,mechanical
1481,antitachycardia
1482,control group
1483,atrial explants
1484,p38α
1485,nonischemic
1486,subset
1487,conduction
1488,sub-sample
1489,milliseconds
1490,physiology
1491,physiological
1492,dialysis-dependent
1493,liver
1494,ischemia
1495,assist
1496,ablation
1497,adult
1498,interrelated
1499,copd
1500,grain
1501,non-cachectic
1502,trigger
1503,midregional proanp
1504,examined
1505,histologically
1506,endoplasmic reticulum
1507,hemodynamic
1508,delay
1509,prediction model
1510,performers
1511,age group
1512,resistive
1513,2+)-uptake
1514,thousand
1515,gait
1516,6mwt
1517,practice-level
1518,structure
1519,atropine
1520,noninvasive
1521,parallel
1522,ingenuity
1523,full-length
1524,mo
1525,infusions
1526,phospholamban
1527,double-knockout
1528,nonstandardized
1529,2-vessel
1530,arrhythmia
1531,angioplasty
1532,post-translational
1533,discharged
1534,age-by-lvef
1535,life-sustaining
1536,adjustment
1537,normalizing
1538,rats
1539,per capita
1540,over-represented
1541,time integral
1542,deacetylases
1543,surviving
1544,nitric oxide
1545,α-myosin
1546,electrocardiographers
1547,infrequent
1548,narrow
1549,activation sequence
1550,end stage
1551,cost-effectiveness
1552,chest
1553,cardiac magnetic resonance
1554,sulfonylureas
1555,micrornas
1556,refractory right heart failure
1557,differential
1558,pvf
1559,extend
1560,projecting
1561,trainings per week
1562,lvad
1563,choline
1564,drawn
1565,individualized
1566,valvular
1567,data sources
1568,pressure-overload-induced heart failure
1569,co-morbidities
1570,creatine
1571,subdomains
1572,doxorubicin-induced heart failure
1573,continuity
1574,nested
1575,perfusion
1576,deter
1577,transseptal catheterisation
1578,social
1579,ch
1580,multicenter
1581,hypertensive
1582,slower
1583,increases
1584,prognostic factors
1585,bhlh
1586,accounting
1587,rvpo
1588,countries
1589,embryonic
1590,brachial
1591,atherosclerosis
1592,complex
1593,chemotherapy-induced
1594,randomized trials
1595,care system
1596,lesions
1597,within-day
1598,meta-analysis
1599,despite
1600,subjected
1601,bromodomain
1602,hypertrophy
1603,nbdmards
1604,electrocardiographic
1605,method
1606,conducting
1607,wall stress
1608,uptitration
1609,stretch
1610,integrate
1611,18-year-old
1612,organizations
1613,program
1614,post-translational states
1615,behind
1616,nitroxyl
1617,design
1618,pressure
1619,transformed
1620,time-dependent covariates
1621,major
1622,bpm
1623,shortcomings
1624,pay-for-performance
1625,economic
1626,across-the-board
1627,measurement systems
1628,nondeveloped countries
1629,percutaneous
1630,first week
1631,slowed
1632,barriers
1633,exhibit
1634,drugs
1635,rm
1636,hypoalbuminemia
1637,initiated
1638,enhancement
1639,pde2
1640,working hearts
1641,enrollment
1642,formed
1643,women
1644,volunteers--a
1645,carrying
1646,correlation
1647,congestive
1648,endothelin
1649,u.s.
1650,secondary end point
1651,united states
1652,upper 80
1653,pigs
1654,conduction abnormalities
1655,annular size
1656,hospitalizations
1657,focusing
1658,uncontrolled
1659,exposed
1660,standard
1661,right heart failure
1662,nonspecific
1663,biopsy
1664,deactivation
1665,time interval
1666,therapies
1667,growth factor
1668,province of québec
1669,degenerative
1670,left ventricular midpapillary level
1671,embase
1672,contextual framework
1673,distribution
1674,researchers
1675,myocyte diameter
1676,left ventricular diastolic function
1677,well-recognised
1678,operation
1679,enriched
1680,counterbalance
1681,american college of cardiology
1682,decrease
1683,diuretic therapy
1684,clinical
1685,attenuated
1686,lb
1687,study-a
1688,wave
1689,myocyte
1690,energy production
1691,reduced
1692,dobutamine
1693,clinical modification
1694,hretn
1695,feasibility study
1696,strokes
1697,coordinate
1698,province of alberta
1699,cardiopulmonary resuscitation
1700,clin
1701,refuse
1702,pro-adrenomedullin
1703,ischemic-hypertensive
1704,right ventricle
1705,ejection fractions
1706,accompanied
1707,beats
1708,pro-b-type
1709,lying
1710,hno
1711,shaping
1712,americans
1713,nontraumatic
1714,parametrized
1715,erc
1716,molecular
1717,post-pd
1718,mouse
1719,cost-effectiveness ratios
1720,fee-for-service
1721,neuronal stressors
1722,bcl-2
1723,acute kidney
1724,clinical variables
1725,twist
1726,co-ordinated
1727,dnx
1728,long time
1729,functioning
1730,myocardial tissue
1731,air pollution
1732,atherosclerotic
1733,via
1734,bridge
1735,general populations
1736,clinical care
1737,synchrony
1738,main outcomes
1739,health-care
1740,random-effects
1741,multisite
1742,energy transfer-based
1743,transcription factors
1744,np
1745,lean
1746,detecting
1747,evaluating
1748,strategies
1749,cpgs
1750,self-care
1751,fever
1752,atrial pressure
1753,high-risk
1754,postoperatively
1755,10-year
1756,at
1757,endopeptidase
1758,cpr
1759,elevation
1760,9-s
1761,afterload
1762,aha
1763,confidence intervals
1764,intervention
1765,ages
1766,shunts
1767,postmarketing
1768,operations
1769,echo-doppler
1770,activation
1771,pathological
1772,sodium-restricted dash
1773,time-dependent
1774,platelet-activating factor
1775,examine
1776,skinfold thickness
1777,increase above
1778,chinese
1779,rotterdam
1780,high-sensitivity
1781,hypokalemia
1782,laboratory
1783,basis
1784,pump-exchange
1785,uncommon
1786,single-arm
1787,likelihood ratio
1788,longitudinal strain
1789,b-type
1790,circulatory derangement
1791,therapy
1792,new jersey
1793,velocity
1794,surgically
1795,integrated
1796,nephrectomy
1797,high-cost
1798,stenting
1799,exerts
1800,anti-neoplastic
1801,hf-ref
1802,end-diastolic pressure
1803,direct
1804,concomitant
1805,intake
1806,cf
1807,interatrial shunting
1808,guidelines
1809,rotation
1810,moves
1811,histone
1812,atrioventricular delay
1813,ontario
1814,duration of antiplatelet
1815,diuretic resistant
1816,deferred in dialysis-dependent patients
1817,cross
1818,caspase
1819,cost of the intervention
1820,biology
1821,separate
1822,re-hospitalization
1823,renin-angiotensin-aldosterone
1824,infusion
1825,rna
1826,time-limited
1827,assessed
1828,paediatric
1829,hfvt(+)
1830,width
1831,aetiologies
1832,blocks
1833,fraction
1834,blood-flow paths
1835,severe
1836,moderate-intensity
1837,challenges
1838,all-cause medical
1839,degree
1840,ethnic groups
1841,act
1842,extracellular flux analyzer
1843,differential analysis
1844,thromboembolic
1845,contractile
1846,association
1847,2-year
1848,inhospital
1849,peptides
1850,japan
1851,pressure-overload
1852,contractility
1853,contrasting
1854,safe
1855,postischemic heart failure
1856,circumflex
1857,secondary
1858,myocardial
1859,scientific
1860,noncardiologist
1861,3-year mortality
1862,abdominal
1863,refill
1864,non-aa
1865,driving
1866,advances
1867,no
1868,radiation
1869,gluconeogenesis
1870,congenital
1871,protocol-driven
1872,central end-systolic pressure
1873,left ventricular tissue
1874,model
1875,physiologic
1876,euthanization
1877,algorithms
1878,hazard ratio
1879,channel-dependent
1880,enhancing
1881,amyloidotic
1882,breathlessness
1883,main
1884,clinical composite
1885,single-center
1886,wall
1887,danish
1888,cad
1889,transforming
1890,confounders
1891,reperfusion
1892,percentiles
1893,telehealth
1894,lesion
1895,studies
1896,core
1897,care unit
1898,underlie
1899,transmitral
1900,frail
1901,oht
1902,biomarkers
1903,cellular responses
1904,free wall
1905,anemic
1906,tachycardic
1907,monitor
1908,randomized control studies
1909,normal
1910,left ventricular ejection time
1911,hypertrophic
1912,contrast
1913,crossover
1914,all-cause mortality
1915,attrition
1916,fiber
1917,confounding
1918,rate-control
1919,electric
1920,dt
1921,sympathetic
1922,cardiologists
1923,interactions
1924,psychometric
1925,coupled
1926,myocardial infarction-both
1927,metric
1928,clinical setting
1929,flow-mediated dilatation
1930,noted above
1931,retention
1932,leaflet repair
1933,linked
1934,aortic blood flow
1935,processes
1936,breathing
1937,cardiogenic shock
1938,crf
1939,twofold
1940,gating
1941,ivabradine-treated
1942,regions
1943,germline
1944,overweight
1945,tension
1946,nonfunctional channels
1947,healthcare
1948,irs2
1949,tachypacing-induced
1950,tac-induced
1951,at the apex
1952,predictors
1953,resynchronization
1954,fractions
1955,acs
1956,rs10927887
1957,age of legal majority
1958,pacing
1959,blacks
1960,deranged
1961,subproteome
1962,cardiorespiratory
1963,ckd
1964,annular plane
1965,antiarrhythmic
1966,3-year
1967,play
1968,mrna
1969,hipsc-cms
1970,rest
1971,rheumatic
1972,haplotype
1973,al
1974,allocation ratio
1975,validation
1976,hscrp
1977,intensive
1978,little
1979,asymptomatic
1980,blood pressure control
1981,medical
1982,beta-adrenergic
1983,anticoagulants
1984,right heart
1985,treated
1986,systolic ventricular
1987,emission
1988,blood
1989,cxl-1020
1990,managing
1991,tomographic angiography
1992,reactivate
1993,subtle
1994,systolic heart failure
1995,specialty
1996,clinician
1997,mr
1998,constants
1999,into
2000,p70s6k-ser
2001,failing
2002,black
2003,non-invasively
2004,serum
2005,environment
2006,undertaken
2007,leaflet resection
2008,abnormal chamber
2009,carcinoma
2010,hydrolysis
2011,cardioverter-defibrillator
2012,devices
2013,hyperacetylation
2014,perturbed bone morphogenetic protein
2015,cfa
2016,cardiac
2017,hg
2018,centrifugal flow pump
2019,btt
2020,left-hand
2021,admissions
2022,ankle-brachial index
2023,acute heart failure
2024,longitudinal change
2025,renin
2026,power
2027,discharge
2028,non-ischemic
2029,pioglitazone
2030,higher-than-expected
2031,left ventricular base
2032,bb
2033,blood pressure
2034,area under the curve
2035,extending
2036,potassium
2037,clinical effects
2038,intubated
2039,low-volume
2040,period
2041,strong
2042,rabbits
2043,participating
2044,difference-in-differences
2045,dramatic
2046,6-minute
2047,fit
2048,uptake
2049,case-control
2050,regulates
2051,intervals
2052,nonmitochondrial
2053,linearly
2054,neprilysin
2055,abnormalities
2056,level of agreement
2057,nursing
2058,post-aac
2059,mixed
2060,end of life
2061,device-related
2062,stand-alone
2063,either
2064,transfusion
2065,hhf
2066,overexpress
2067,per se
2068,gait therapy
2069,main outcome
2070,clinical follow-up of heart failure
2071,msec
2072,quality-of-life score
2073,heart failure admission
2074,p=0·035
2075,centre
2076,senescence
2077,humanized
2078,health
2079,telemonitoring
2080,muscle mass
2081,latter
2082,uk
2083,dash
2084,bets
2085,expenditures
2086,mid lad
2087,precipitating factor
2088,of hope
2089,venoarterial dilation
2090,mena
2091,study selection
2092,agonist
2093,tachycardia-induced
2094,disciplines
2095,caspase-3
2096,coronary perfusion
2097,developmental
2098,western australian
2099,observational study
2100,common
2101,during
2102,low-quality
2103,rr
2104,antibodies
2105,oxygen
2106,american
2107,interval
2108,died
2109,nbdmard
2110,infarct
2111,signalling cascades
2112,ss20
2113,branches
2114,intolerance
2115,english
2116,tissue
2117,abstract
2118,biomarker-guided
2119,age-specific
2120,expansion
2121,myocardial collagen
2122,young woman
2123,fractional
2124,guiding
2125,parallel-group
2126,overlapped
2127,low-dose
2128,two
2129,adoption of heart failure guidelines
2130,end-of-life
2131,bioprosthetic
2132,assisted
2133,pacemakers
2134,biventricular
2135,longitudinal
2136,monoclonal
2137,decade
2138,out-patient
2139,qtv
2140,(123)i-mibg
2141,scaffold
2142,basal heart rate
2143,hospitalization
2144,rhythm-control
2145,irs1
2146,pyridostigmine
2147,strip
2148,diagnostic
2149,signalosome
2150,intermuscular
2151,medline
2152,pressure gradient
2153,assay
2154,allopurinol
2155,rise
2156,titrated
2157,prolapse
2158,atropine infusion
2159,myocardial diastolic
2160,venous
2161,intermediate
2162,doppler
2163,ans
2164,placebo-treated
2165,high-frequency
2166,grading
2167,networks
2168,reduction of sympathetic tone
2169,men
2170,better-than-usual
2171,newly
2172,percutaneous coronary
2173,real-time
2174,lower natremia
2175,proteins
2176,awful
2177,sex
2178,erythropoiesis-stimulating
2179,2-erk1
2180,1.5-t
2181,susceptibility
2182,expressing
2183,angiogenesis
2184,recruitment
2185,functions
2186,physical
2187,natriuretic peptides
2188,full length
2189,activity
2190,advancement of science
2191,january
2192,redesigned
2193,thirty-seven
2194,emotional
2195,nephropathy
2196,severe-end-stage
2197,factors
2198,basal contractility
2199,exogenous
2200,co
2201,402.x1
2202,anti-inflammatory
2203,interventions
2204,recovery
2205,length of stay
2206,end diameter
2207,unloading
2208,hgb
2209,sequence-specific
2210,hospitalisations
2211,burden
2212,four
2213,pef
2214,myoctyes
2215,health-related
2216,transgenic
2217,icd
2218,differentially impair
2219,chf
2220,on
2221,energy
2222,mutant
2223,clinical trials
2224,characteristics
2225,depolarization
2226,creatinine
2227,elderly
2228,fluctuations
2229,plays
2230,empirically
2231,process
2232,matching
2233,ischemic cerebrovascular
2234,inducible
2235,systemic
2236,mix
2237,connection
2238,test-retest
2239,beneficial effect
2240,tracked
2241,radial
2242,exhibited
2243,serum factors
2244,proportion of deficits
2245,loading
2246,decompensated
2247,actrn12610001087044
2248,isoprenaline
2249,joint effect
2250,high-quality
2251,oxygenation
2252,interfere
2253,processed
2254,nervous system
2255,reduction of cardiac
2256,altered
2257,lower socioeconomic
2258,centrifugal-flow
2259,s'lateral
2260,remote monitoring
2261,cpcs
2262,conductance
2263,mediterranean
2264,counterparts
2265,elevated left atrial pressure
2266,infarction
2267,subunits
2268,subproteomes
2269,stiffness
2270,end-stage
2271,untreated
2272,seven
2273,slow
2274,infarction-related
2275,europe
2276,by
2277,norepinephrine
2278,patterns
2279,continuity of care
2280,baroreflex
2281,mechanisms
2282,transcatheter
2283,non-linear
2284,echocardiograms
2285,participant
2286,cgmp
2287,mass spectrometric
2288,cardioprotection
2289,regimen
2290,technical
2291,double-blind
2292,device
2293,surgical
2294,6-week
2295,acute hospital
2296,monitoring
2297,p70s6k
2298,404.x3
2299,centrally
2300,cardiac-resynchronization
2301,3-month
2302,decreases in heart failure-related mortality
2303,co-primary
2304,cardiology-cardiovascular surgery
2305,partially
2306,east
2307,subcellular
2308,clcnka
2309,treatment
2310,under
2311,followed
2312,post-transplant
2313,brief
2314,warrants
2315,meq
2316,outline
2317,direct comparison
2318,worldwide
2319,myofiber
2320,low
2321,post hoc
2322,parasympathetic control
2323,rheumatoid
2324,postoperative mortality
2325,etiologic
2326,canada
2327,persistent
2328,halt
2329,paradigm
2330,thromboembolism
2331,overstimulation
2332,immunohistochemistry
2333,mechanics
2334,main effect
2335,coronary
2336,endothelial
2337,tolerance
2338,resistin
2339,wild-type
2340,western blot
2341,therapeutic potential
2342,rgk
2343,geometry
2344,histological
2345,left ventricular systolic dysfunction
2346,delineated
2347,fixed-rate
2348,practice
2349,hypertension
2350,clustering
2351,visits
2352,72-hour
2353,western
2354,forty-six
2355,advanced
2356,cxl-1051
2357,unanchors
2358,collateral
2359,15-ml
2360,monophosphate
2361,stent
2362,acp
2363,acting
2364,metabolic
2365,af
2366,classic
2367,clinical practice
2368,transmitral flow
2369,amplitude
2370,american heart association
2371,correlation coefficient
2372,statistic
2373,beta
2374,pulse
2375,university of michigan
2376,searched
2377,elevated
2378,well-being
2379,paced
2380,cachexia
2381,evolving
2382,prescriptive
2383,test
2384,triangular resection
2385,vehicle-treated
2386,training
2387,upr
2388,assembly
2389,longitudinal systolic strain
2390,mitral
2391,10-week
2392,processes of care
2393,tethering
2394,driveline
2395,dhand
2396,cation
2397,central
2398,statistical
2399,likelihood
2400,years of age
2401,circulatory
2402,uneventful
2403,characterized
2404,valve
2405,hospitals
2406,tracking
2407,absorptiometry
2408,regulation
2409,ec
2410,engage
2411,nationwide
2412,or
2413,unfolded
2414,ring annuloplasty
2415,nordic walking
2416,outpatient
2417,voltage-gated
2418,systemic blood pressure
2419,canadian
2420,consumption
2421,congenital abnormalities
2422,inhibitory
2423,excursion
2424,non-fatal stroke
2425,risk of heart failure
2426,mutant mice
2427,strain
2428,reliability
2429,hfpsi
2430,comparisons
2431,diuretic
2432,broader
2433,left-to-right
2434,β-blockade
2435,professionals
2436,loop diuretics
2437,prevention
2438,emotional stress
2439,debilitating
2440,nationally
2441,lability
2442,monocytes
2443,atrial area
2444,e'mean
2445,positively
2446,classification of diseases
2447,québec
2448,echocardiographic
2449,modestly
2450,treating
2451,subvalvular
2452,hfvt(-)
2453,adult population
2454,albeit
2455,scar
2456,diuretic effect
2457,triggers
2458,pad
2459,muscle strips
2460,sudden
2461,cardiomyopathy
2462,multivariate
2463,atrial
2464,guideline
2465,diastolic failure
2466,randomized trial
2467,explants
2468,iron-deficient
2469,time frame
2470,composite end point of esrd
2471,lower mortality
2472,primary oscillations
2473,in the united states
2474,lvh
2475,3.5-fold
2476,cardiotoxicity
2477,playing
2478,across
2479,pna
2480,prognostic factor
2481,work
2482,occlusion
2483,bolus
2484,herein
2485,subpulmonary ventricle
2486,downward
2487,dodson
2488,diet adherence
2489,age
2490,normalized
2491,fontan
2492,psss
2493,endpoint
2494,functional
2495,goal-directed
2496,mean
2497,phase
2498,insertion
2499,exertional
2500,phosphocreatine
2501,line
2502,new york
2503,receiver
2504,reducing
2505,years
2506,defined
2507,wasting
2508,an
2509,key
2510,procedure-related
2511,accompany
2512,later
2513,predictors of mortality
2514,vt
2515,time span
2516,pulse sequence
2517,internists
2518,inhibition
2519,gls
2520,interleukin receptor
2521,beat-to-beat
2522,glucose
2523,ng
2524,conditional
2525,oscillatory ventilation
2526,systematic
2527,heart
2528,extracellular matrix
2529,bundle-branch
2530,mlhf
2531,arrhythmia-related
2532,orchestrate
2533,cause of mortality
2534,tachycardia
2535,defibrillators
2536,isoproterenol
2537,abnormal
2538,mixed-methods
2539,bottleneck
2540,exploratory factor
2541,gadolinium-chelate
2542,end point
2543,parasympathetic neurotransmission
2544,bradyarrhythmias
2545,months
2546,midpapillary
2547,oversewing
2548,m2
2549,remarkable
2550,age-
2551,point of death
2552,ang
2553,cyclase
2554,out
2555,self-identified
2556,ml
2557,etidronate
2558,upregulated
2559,rationale
2560,early-outgrowth
2561,coprimary
2562,3m
2563,6-month survival
2564,exponent
2565,arterial tonometry
2566,regimens
2567,peptide
2568,angina
2569,ejection
2570,die
2571,fm
2572,mt
2573,panel
2574,liver-specific
2575,aor
2576,blunts
2577,left ventricular dilatation
2578,clinical trials-enriching
2579,expectancy
2580,pre-participation
2581,2+)-pump
2582,lung
2583,propensity score
2584,industrial
2585,sv
2586,4-year
2587,catheterization
2588,52-year-old
2589,pacemaker
2590,levels
2591,inconsistent
2592,taxonomy
2593,mechanism
2594,sought
2595,inflow
2596,dipeptidyl
2597,signalling pathways
2598,left ventricular
2599,nonfailing
2600,age-matched
2601,electrical
2602,colony-forming units
2603,controls
2604,clinicians
2605,experimental
2606,general population
2607,q66p
2608,peak vo2
2609,biological
2610,epinephrine
2611,electrical stimulation
2612,time of admission
2613,elevated resistin
2614,moderate
2615,end-tidal
2616,vegf
2617,inducing
2618,heart failure
2619,rat
2620,adhesion
2621,inappropriate
2622,readmission reduction
2623,stress
2624,prolonged electromechanical delay
2625,severely
2626,2-way
2627,active
2628,denervation
2629,elevated mena
2630,pulmonary hypertension
2631,length-force relationship
2632,apex
2633,conjunction
2634,magnetic resonance angiography
2635,induced
2636,annular
2637,minutes
2638,modern society
2639,urea
2640,uti
2641,rural
2642,wistar
2643,maladaptive
2644,(-)-epicatechin-rich
2645,explanted
2646,acute care hospital for hf
2647,multimarker-based
2648,fractal
2649,achieving
2650,benefit
2651,stenotic
2652,thirds
2653,electromechanical
2654,enrolled
2655,regurgitation
2656,left ventricular dysfunction
2657,observational studies
2658,progenitors
2659,atypical
2660,t1
2661,aim
2662,lcx
2663,contractile reserve
2664,icd-hf
2665,secondary endpoints
2666,chemotherapy
2667,shift
2668,acute myocardial infarction
2669,grip
2670,evidence-based practices
2671,waist circumference
2672,nonprescribing
2673,surgical ring
